Showing results (91-100 of 224) with videos related to

Sort By:
Pageof 23
Clinical Rheumatology|January 15, 2015
Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologistsDavid Grabowski, Bradley Henderson, Dennis Lam, et al.
The Journal of Rheumatology|October 19, 2010
Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registriesAllan Gibofsky, William R Palmer, Edward C Keystone, et al.
Arthritis and Rheumatism|October 31, 2007
Increased expression of discoidin domain receptor 2 is linked to the degree of cartilage damage in human knee joints: a potential role in osteoarthritis pathogenesisIlse-Gerlinde Sunk, Klaus Bobacz, Jochen G Hofstaetter, et al.
Arthritis Research & Therapy|November 30, 2013
Patient education, disease activity and physical function: can we be more targeted? A cross sectional study among people with rheumatoid arthritis, psoriatic arthritis and hand osteoarthritisRăzvan G Drăgoi, Mwidimi Ndosi, Martina Sadlonova, et al.
Rheumatology and Therapy|February 27, 2025
Synergistic Improvements in Synovitis, Enthesitis, and Patient-Reported Outcomes for Patients with Psoriatic Arthritis Treated with Ixekizumab in SPIRIT TrialsLars-Erik Kristensen, Dennis McGonagle, Martin Rudwaleit, et al.
Bulletin of the NYU Hospital for Joint Diseases|July 17, 2010
Progress toward the development of a new definition of remission in rheumatoid arthritisMaarten Boers, David T Felson, George Wells, et al.
Wiener Klinische Wochenschrift|January 3, 2012
Effects of 18β-Glycyrrhetinic acid in hTNFtg mice - a model of rheumatoid arthritisAntonia Puchner, Silvia Hayer, Birgit Niederreiter, et al.
Arthritis and Rheumatism|May 18, 2004
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trialEdward C Keystone, Arthur F Kavanaugh, John T Sharp, et al.
The Journal of Rheumatology|October 3, 2014
Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis--results from the Canadian Early Arthritis Cohort (CATCH)Bindee Kuriya, Juan Xiong, Gilles Boire, et al.
The Journal of Rheumatology|November 19, 2013
Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extensionEdward C Keystone, Ferdinand C Breedveld, Désirée van der Heijde, et al.
Pageof 23